Covid19 Clinical Trial - Clinical Trial for Oral Formula of Vanillin &

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Clinical Trial Summary

- The study is a randomized clinical trial to assess a natural formula of vanillin & wheat germ oil to treat and stop the clinical progression of COVID-19. - The study aims to treat people with mild-to-moderate COVID-19 before their cases become severe. - The study duration is a 5-day experimental intervention and an extended 4 weeks follow up.

See also
	Status	Clinical Trial	Phase
	Completed	`NCT04486482` - A Clinical Study to Assess the Physiologic Effects of KB109 in Patients With COVID-19 on Gut Microbiota Structure and Function	N/A
	Completed	`NCT04414124` - A Clinical Study to Assess the Natural History of COVID-19 and Effects of KB109 and Supportive Self-care in Outpatients With Mild-to-moderate COVID-19	N/A

NCT number	NCT05157139
Study type	Interventional
Source	Alexandria University
Contact
Status	Recruiting
Phase	Phase 2/Phase 3
Start date	November 1, 2021
Completion date	April 2022

Clinical Trial for Oral Formula of Vanillin and Wheat Germ Oil for Treatment of Mild and Moderate COVID-19 Viral Disease

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms